Abstract
In adults, the presence of the BRAF V600E mutation in papillary thyroid cancer (PTC) has been demonstrated to be strongly associated with aggressive cancer-cell characteristics and poor patient prognosis. In contrast, the frequency of this mutation in pediatric PTC has undergone limited study, and the few available estimates range from 0 to 63%. Furthermore, the role of the BRAF V600E mutation in pediatric PTC is controversial; thus, the present study aimed to investigate the prevalence and role of the BRAF V600E mutation in 48 pediatric patients with PTC, aged 3–13 years. Of these patients, 41 were diagnosed with classic PTC, five were found to have a follicular variant of PTC, and two to exhibit a diffuse sclerosing PTC variant. The BRAF V600E mutation was identified to be present in 35.4% of the 48 analyzed patients, and in 41.5% of the patients diagnosed with classical PTC. Furthermore, the presence of the BRAF V600E mutation was found to be associated with a patient age at diagnosis of less than ten years (P=0.011), the performance of a thyroidectomy (P=0.03), exhibited tumor multifocality (P=0.02) and/or extra-thyroidal invasion (P=0.003), and both a low MACIS (Metastases, Age, Completeness of resection, Invasion, Size)(P=0.036) and AMES (Age, Metastasis, Extent of tumor, Size)(P=0.001) score. Together, these data suggest that the presence of the BRAF V600E mutation may be negatively correlated with partial aggressive clinicopathological features of pediatric PTC.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., Jemal, A., Yu, X.Q., and He, J. (2016). Cancer statistics in China, 2015. CA Cancer J Clin 66, 115–132.
Czarniecka, A., Kowal, M., Rusinek, D., Krajewska, J., Jarzab, M., Stobiecka, E., Chmielik, E., Zembala-Nozynska, E., Poltorak, S., Sacher, A., Maciejewski, A., Zebracka-Gala, J., Lange, D., Oczko-Wojciechowska, M., Handkiewicz-Junak, D., and Jarzab, B. (2015). The risk of relapse in papillary thyroid cancer (PTC) in the context of BRAFV600E mutation status and other prognostic factors. PLoS ONE 10, e132821.
Davies, H., Bignell, G.R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M.J., Bottomley, W., Davis, N., Dicks, E., Ewing, R., Floyd, Y., Gray, K., Hall, S., Hawes, R., Hughes, J., Kosmidou, V., Menzies, A., Mould, C., Parker, A., Stevens, C., Watt, S., Hooper, S., Wilson, R., Jayatilake, H., Gusterson, B.A., Cooper, C., Shipley, J., Hargrave, D., Pritchard-Jones, K., Maitland, N., Chenevix-Trench, G., Riggins, G.J., Bigner, D.D., Palmieri, G., Cossu, A., Flanagan, A., Nicholson, A., Ho, J.W.C., Leung, S.Y., Yuen, S.T., Weber, B.L., Seigler, H.F., Darrow, T.L., Paterson, H., Marais, R., Marshall, C.J., Wooster, R., Stratton, M.R., and Futreal, P.A. (2002). Mutations of the BRAF gene in human cancer. Nature 417, 949–954.
Dzodic, R., Buta, M., Markovic, I., Gavrilovic, D., Matovic, M., Djurisic, I., Milovanovic, Z., Pupic, G., Tasic, S., and Besic, N. (2014). Surgical management of well-differentiated thyroid carcinoma in children and adolescents: 33 years of experience of a single institution in Serbia. Endocr J 61, 1079–1086.
Elisei, R., Viola, D., Torregrossa, L., Giannini, R., Romei, C., Ugolini, C., Molinaro, E., Agate, L., Biagini, A., Lupi, C., Valerio, L., Materazzi, G., Miccoli, P., Piaggi, P., Pinchera, A., Vitti, P., and Basolo, F. (2012). TheBRAFV600E mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab 97, 4390–4398.
Francis, G.L., Waguespack, S.G., Bauer, A.J., Angelos, P., Benvenga, S., Cerutti, J.M., Dinauer, C.A., Hamilton, J., Hay, I.D., Luster, M., Parisi, M.T., Rachmiel, M., Thompson, G.B., Yamashita, S., and Yamashita, S. (2015). Management guidelines for children with thyroid nodules and differentiated thyroid cancer. Thyroid 25, 716–759.
Givens, D.J., Buchmann, L.O., Agarwal, A.M., Grimmer, J.F., and Hunt, J.P. (2014). BRAFV600E does not predict aggressive features of pediatric papillary thyroid carcinoma. Laryngoscope 124, e389–E393.
Henke, L.E., Perkins, S.M., Pfeifer, J.D., Ma, C., Chen, Y., DeWees, T., and Grigsby, P.W. (2014). BRAFV600E mutational status in pediatric thyroid cancer. Pediatr Blood Cancer 61, 1168–1172.
Hogan, A.R., Zhuge, Y., Perez, E.A., Koniaris, L.G., Lew, J.I., and Sola, J.E. (2009). Pediatric thyroid carcinoma: incidence and outcomes in 1753 patients. J Surgical Res 156, 167–172.
LaFranchi, S.H. (2015). Inaugural management guidelines for children with thyroid nodules and differentiated thyroid cancer: children are not small adults. Thyroid 25, 713–715.
Li, C., Lee, K.C., Schneider, E.B., and Zeiger, M.A. (2012). BRAFV600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis. J Clin Endocrinol Metab 97, 4559–4570.
Liu, C., Chen, T., and Liu, Z. (2016). Associations between BRAFV600E and prognostic factors and poor outcomes in papillary thyroid carcinoma: a meta-analysis. World J Surg Onc 14, 241.
Parisi, M.T., Eslamy, H., and Mankoff, D. (2016). Management of differentiated thyroid cancer in children: focus on the American Thyroid Association Pediatric Guidelines. Seminars Nucl Med 46, 147–164.
Penko, K., Livezey, J., Fenton, C., Patel, A., Nicholson, D., Flora, M., Oakley, K., Tuttle, R.M., and Francis, G. (2005). BRAF mutations are uncommon in papillary thyroid cancer of young patients. Thyroid 15, 320–325.
Petrulea, M.S., Plantinga, T.S., Smit, J.W., Georgescu, C.E., and Netea-Maier, R.T. (2015). PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma. Cancer Treatment Rev 41, 707–713.
Roring, M., and Brummer, T. (2012). Aberrant B-Raf signaling in human cancer—10 years from bench to bedside. Crit Rev Oncog 17, 97–121.
Sassolas, G., Hafdi-Nejjari, Z., Ferraro, A., Decaussin-Petrucci, M., Rousset, B., Borson-Chazot, F., Borbone, E., Berger, N., and Fusco, A. (2012). Oncogenic alterations in papillary thyroid cancers of young patients. Thyroid 22, 17–26.
Siegel, R.L., Miller, K.D., and Jemal, A. (2015). Cancer statistics, 2015. CA Cancer J Clin 65, 5–29.
Vergamini, L.B., Frazier, A.L., Abrantes, F.L., Ribeiro, K.B., and Rodriguez-Galindo, C. (2014). Increase in the incidence of differentiated thyroid carcinoma in children, adolescents, and young adults: a population-based study. J Pediatrics 164, 1481–1485.
Ward, E., DeSantis, C., Robbins, A., Kohler, B., and Jemal, A. (2014). Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin 64, 83–103.
Xing, M., Haugen, B.R., and Schlumberger, M. (2013). Progress in molecular-based management of differentiated thyroid cancer. Lancet 381, 1058–1069.
Xing, M., Alzahrani, A.S., Carson, K.A., Shong, Y.K., Kim, T.Y., Viola, D., Elisei, R., Bendlova, B., Yip, L., Mian, C., Vianello, F., Tuttle, R.M., Robenshtok, E., Fagin, J.A., Puxeddu, E., Fugazzola, L., Czarniecka, A., Jarzab, B., O’Neill, C.J., Sywak, M.S., Lam, A.K., Riesco-Eizaguirre, G., Santisteban, P., Nakayama, H., Clifton-Bligh, R., Tallini, G., Holt, E.H., and Sykorova, V. (2015). Association between BRAFV600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 33, 42–50.
Yarchoan, M., LiVolsi, V.A., and Brose, M.S. (2015). BRAF mutation and thyroid cancer recurrence. J Clin Oncol 33, 7–8.
Acknowledgements
This work was supported in part by Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201508), Beijing Municipal Science and Technology Project (D131100005313014), and Beijing Health System Top Level Health Technical Personnel Training Plan (20153079).
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Geng, J., Wang, H., Liu, Y. et al. Correlation between BRAF V600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma. Sci. China Life Sci. 60, 729–738 (2017). https://doi.org/10.1007/s11427-017-9083-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-017-9083-8